Responsible for licensing of company's discovery platforms and development programs. Orum's dual-precision TPD² approach leverages the strengths of both targeted protein degraders (TPDs) and antibody drug conjugates (ADCs), while overcoming limitations of each.

Responsible for business development and operational aspects of Magenta's targeted conditioning programs, including MGTA-117. Role included establishing and maintaining strategic relationships to support research and CMC activities, with a focus on conditioning portfolio

Licensing of company's proprietary antibody-drug conjugate platform for target-specific oncology drug discovery, partnering wholly owned pipeline assets, scouting for complimentary technologies, suppporting external biomarker/CDx collaborations, and providing commercial support and analysis for in-house product development

Contributed to 20+ client engagements with several top 25 pharmaceutical companies for Decision Resources' consulting practice; role on project teams has included: schedule/oversee staff workflow; manage project budgets; liaise with internal senior management and client management to ensure project goals were met; create Excel and PowerPoint deliverablesExecuted a variety of different project work including therapeutic area opportunity assessments, evidence-based competitive analyses, decision modeling, market sizing and forecasting, and assisting in the diligence process for prospective acquisitions or in-licensing opportunities for clientsProject work accross a number of different therapeutic areas including treatment of solid tumors and hematologic malignancies, immune disorders, neuromuscular diseases, and rare genetic disorders

Author of indication-specific syndicated research reports as part of the Immune and Inflammatory disease area team. Areas of expertise include the drug markets for Chronic Obstructive Pulmonary Disease, Benign Prostatic Hyperplasia and Atopic Dermatitis. Gained experience in epidemiology-based forecasting and understanding regulatory and reimbursement processes across the G7 (US, France, Germany, Italy, Spain, UK and Japan).

Research position in discovery chemistry group; involved in the design and synthesis of novel molecular ligands for BMS’s cardiovascular and oncology imaging research programs